Provided by Tiger Trade Technology Pte. Ltd.

Prelude Therapeutics Inc

5.09
-0.2100-3.96%
Pre-market: 5.100.0114+0.22%07:22 EDT
Volume:311.98K
Turnover:1.61M
Market Cap:405.38M
PE:-7.09
High:5.34
Open:5.25
Low:5.06
Close:5.30
52wk High:6.83
52wk Low:0.9807
Shares:79.64M
Float Shares:4.56M
Volume Ratio:0.73
T/O Rate:6.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7183
EPS(LYR):-1.2929
ROE:-57.73%
ROA:-27.15%
PB:3.03
PE(LYR):-3.94

Loading ...

Prelude Therapeutics receives FDA clearance for PRT13722 IND application

TIPRANKS
·
30 mins ago

Prelude Therapeutics Says FDA Clears IND for Prt13722 in Hr+/her2- Breast Cancer

Reuters
·
37 mins ago

Prelude Therapeutics Incorporated - Expects to Begin Enrolling Patients in Q4 2026

THOMSON REUTERS
·
39 mins ago

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (Ind) Application for Prt13722, Its First-in-Class Oral Kat6a Selective Degrader

THOMSON REUTERS
·
39 mins ago

Prelude Therapeutics Stock Rises on Narrower 2Q Loss, Plans to Start Trial for Breast Cancer Drug

Dow Jones
·
Aug 21

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 19

Ovid Therapeutics Q2 Revenue Beats Estimates

Reuters
·
Aug 13

Prelude Therapeutics Incorporated Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Cardiff Oncology Q2 Operating Expenses Fall on Lower R&D Costs

Reuters
·
Aug 12

Bolt Biotherapeutics Q2 Net Loss Narrows on Restructuring and Lower Research Activity

Reuters
·
Aug 12

Prelude Therapeutics Q2 EPS $(0.14) Beats $(0.20) Estimate, Sales $5.704M

Benzinga Earnings
·
Aug 11

Prelude Therapeutics reports Q2 EPS (14c), consensus (19c)

TIPRANKS
·
Aug 11

Prelude Therapeutics Q2 Revenue USD 5.704 Million

THOMSON REUTERS
·
Aug 11

Prelude Therapeutics Q2 EPS USD -0.14

THOMSON REUTERS
·
Aug 11

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
Aug 11

Prelude Therapeutics Incorporated Expected to Post a Loss of 20 Cents a Share - Earnings Preview

Reuters
·
Aug 10

Prelude Therapeutics Price Target Maintained with a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
Jul 29

Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline

TIPRANKS
·
Jul 28

Prelude Therapeutics Shareholders Back Leadership and Governance

TIPRANKS
·
Jun 11

Prelude Therapeutics shareholders elect three directors at annual meeting

Reuters
·
Jun 11